Joseph Wu

Also affiliated with Children's Hospital of Philadelphia, Pfizer (United States), Baylor College of Medicine, Cardiovascular Institute of the South, Kunming Medical University, Shanghai Innovative Research Center of Traditional Chinese Medicine, Suzhou University of Science and Technology, Innovation Team (China), Shanghai Skin Disease Hospital, Henan Institute of Science and Technology, Stanford University

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance”.

Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance

Annals of the Rheumatic Diseases(2022)10.1136/ard-2022-222259

N/A

5.2DataRank · unranked

206 citations

Maya H Buch, Maxime Dougados, Deepak L. Bhatt, Jon T. Giles, Steven R. Ytterberg +11 more

Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial

Annals of the Rheumatic Diseases(2022)10.1136/ard-2022-222543

N/A

4.5DataRank · unranked

163 citations

Kunihiro Yamaoka, Yi‐Hsing Chen, Deepak L. Bhatt, Levent M Gunay, Naonobu Sugiyama +7 more

Etrasimod as a treatment for eosinophilic oesophagitis (VOYAGE): a double-blind, placebo-controlled, randomised, phase 2 trial

The Lancet. Gastroenterology & hepatology(2025)10.1016/s2468-1253(25)00062-7

N/A

0.473DataRank · unranked

15 citations

Margaret H. Collins, Albert J. Bredenoord, Hamish Philpott, Luc Biedermann, Márjori Dulcine +11 more